Atossa Therapeutics prices up to $16.5M registered direct offering
What's the deal? Atossa Therapeutics (NASDAQ: ATOS) has priced a registered direct offering with institutional investors for up to $16.5M in gross proceeds. The deal includes 1.36 million shares, or common stock equivalents, along with warrants to purchase up to 2.73 million additional shares.
Why now? The biotech company is raising capital through a private placement at a time when small-cap therapeutics firms frequently tap public and private markets to fund ongoing clinical programmes and operations. The structure — combining shares with warrants — is a common approach for companies looking to sweeten the deal for institutional buyers while maximising proceeds.
What could go wrong? Direct offerings with warrants can dilute existing shareholders significantly. If the warrants are exercised, up to 2.73 million additional shares would enter the market on top of the 1.36 million already issued. That's a substantial increase in share count for a small-cap company, which could weigh on the stock price.
The signal: Small biotech firms continue to rely on structured equity deals to keep the lights on. The inclusion of warrants — effectively giving investors the right to buy more shares later at a set price — reflects the leverage institutional buyers hold in negotiations with capital-hungry therapeutics companies. It's a pattern unlikely to change as long as drug development timelines remain long and expensive.
Read more: Seeking Alpha
